Genprex Gets FDA Orphan Drug Designation For Quaratusugene Ozeplasmid For Treatment Of Small Cell Lung Cancer
Portfolio Pulse from Happy Mohamed
The FDA has granted Genprex's Quaratusugene Ozeplasmid an Orphan Drug Designation for the treatment of small cell lung cancer. This designation provides Genprex with certain benefits, including tax credits, market exclusivity for seven years, and waiver of certain fees.
August 09, 2023 | 3:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genprex's stock may see positive movement due to the FDA's Orphan Drug Designation for Quaratusugene Ozeplasmid. This designation can provide financial and market benefits.
The FDA's Orphan Drug Designation is a significant milestone for Genprex and its Quaratusugene Ozeplasmid. This designation provides Genprex with certain benefits, including tax credits, market exclusivity for seven years, and waiver of certain fees, which can positively impact the company's financials and increase the attractiveness of the stock to investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100